Study #2012-0758
A PILOT STUDY OF LYMPHODEPLETION PLUS ADOPTIVE CELL TRANSFER WITH TGF-Beta RESISTANT (DNRII) TRANSDUCED T-CELLS FOLLOWED BY HIGH DOSE INTERLEUKIN-2 IN PATIENTS WITH METASTATIC MELANOMA
MD Anderson Study Status
Not Accepting
Treatment Agent
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Description
This pilot phase I trial studies the side effects and best dose of genetically modified T-cells followed by aldesleukin in treating patients with stage III-IV melanoma. T-cells are a type of white blood cell that help the body fight infections. Genes that may help the T-cells recognize melanoma cells are placed into the T-cells in the laboratory. Adding these genes to the T cells may help them kill more tumor cells when they are put back in the body. Aldesleukin may enhance this effect by stimulating white blood cells to kill more melanoma cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Study phase:
Phase I
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-463-0259
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.